SGLT2 Inhibitors and Cats With Diabetes: What Have We Learned So Far?

These past few years have been all about the use of FDA approved sodium glucose co-transporter 2 inhibitors (SGLT2i) in the treatment of newly diagnosed cats with diabetes mellitus (DM) in the US. Use of these drugs over the last few years has increased our knowledge and experience with their use in cats. Efficacy and adverse events observed in field studies and clinical experiences will be discussed. Appropriate case selection and monitoring will be detailed. Future applications and potential benefits of SGLT2i in veterinary medicine will be highlighted.